CN104926802B - 用于制备神经氨酸衍生物的方法 - Google Patents

用于制备神经氨酸衍生物的方法 Download PDF

Info

Publication number
CN104926802B
CN104926802B CN201510314576.XA CN201510314576A CN104926802B CN 104926802 B CN104926802 B CN 104926802B CN 201510314576 A CN201510314576 A CN 201510314576A CN 104926802 B CN104926802 B CN 104926802B
Authority
CN
China
Prior art keywords
compound
acid
formula
reaction
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510314576.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104926802A (zh
Inventor
若山雅
若山雅一
鸟山史彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN104926802A publication Critical patent/CN104926802A/zh
Application granted granted Critical
Publication of CN104926802B publication Critical patent/CN104926802B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201510314576.XA 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法 Active CN104926802B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011275819 2011-12-16
JP2011-275819 2011-12-16
CN201280062083.6A CN103974945B (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280062083.6A Division CN103974945B (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法

Publications (2)

Publication Number Publication Date
CN104926802A CN104926802A (zh) 2015-09-23
CN104926802B true CN104926802B (zh) 2018-02-13

Family

ID=48612610

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510314653.1A Pending CN105037309A (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法
CN201510314576.XA Active CN104926802B (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法
CN201280062083.6A Active CN103974945B (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510314653.1A Pending CN105037309A (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280062083.6A Active CN103974945B (zh) 2011-12-16 2012-12-13 用于制备神经氨酸衍生物的方法

Country Status (12)

Country Link
US (2) US20140356625A1 (enExample)
EP (3) EP2960237A1 (enExample)
JP (1) JP6038808B2 (enExample)
KR (1) KR101971311B1 (enExample)
CN (3) CN105037309A (enExample)
BR (1) BR112014014635A2 (enExample)
CA (1) CA2859296C (enExample)
ES (1) ES2640001T3 (enExample)
HK (3) HK1199034A1 (enExample)
IL (2) IL233124A0 (enExample)
IN (1) IN2014MN00971A (enExample)
WO (1) WO2013089168A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032357A1 (zh) * 2013-09-09 2015-03-12 中国科学院上海有机化学研究所 扎那米韦和拉那米韦的中间体及其合成方法
CN113801082B (zh) * 2020-06-12 2024-09-17 博瑞生物医药（苏州）股份有限公司 一种辛酸拉尼米韦的制备方法
CN113801138B (zh) * 2020-06-12 2024-11-29 博瑞生物医药（苏州）股份有限公司 一种一锅法制备辛酸拉尼米韦中间体的方法
KR102405310B1 (ko) * 2020-07-08 2022-06-02 가톨릭대학교 산학협력단 유체의 압력을 이용한 인공 요도괄약근
CN114907301B (zh) * 2021-02-10 2024-05-28 上海医药工业研究院 一种拉尼米韦辛酸酯中间体及其制备方法
CN117814306A (zh) * 2023-07-17 2024-04-05 铭畅生物医药南通有限公司 一种提高唾液酸酯稳定性的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105158A1 (en) * 2000-04-25 2003-06-05 Sankyo Company, Limited Hydrates of a neuraminic acid compound and crystalline forms thereof
WO2008126943A2 (en) * 2007-04-11 2008-10-23 Daiichi Sankyo Company, Limited Method for manufacturing neuraminic acid derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5141897B2 (enExample) * 1972-11-30 1976-11-12
JP2745059B2 (ja) * 1989-03-08 1998-04-28 メクト株式会社 Ｎ―アセチルノイラミン酸ナトリウム・三水和物
GB9325841D0 (en) * 1993-12-17 1994-02-23 Glaxo Group Ltd Chemical compounds
JPH0994768A (ja) * 1995-09-29 1997-04-08 Nippon Electric Ind Co Ltd 車用電動工具
US6340702B1 (en) 1996-07-22 2002-01-22 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
JP3209946B2 (ja) * 1996-07-22 2001-09-17 三共株式会社 ノイラミン酸誘導体
US6451766B1 (en) * 1996-07-22 2002-09-17 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
PT823428E (pt) * 1996-07-22 2002-04-29 Sankyo Co Derivados do acido neuraminico sua preparacao e sua utilizacao em medicina
US7330875B1 (en) 1999-06-15 2008-02-12 Microsoft Corporation System and method for recording a presentation for on-demand viewing over a computer network
AU2001252578A1 (en) 2000-04-25 2001-11-07 Sankyo Company Limited Preventives for influenza
JP3920041B2 (ja) 2000-04-25 2007-05-30 三共株式会社 ノイラミン酸化合物の水和物及び結晶
JP4205314B2 (ja) 2000-04-25 2009-01-07 第一三共株式会社 インフルエンザ予防剤
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
CN101715343B (zh) * 2007-03-07 2012-09-26 第一三共株式会社 流感治疗药
TWI491416B (zh) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
CN102050771A (zh) * 2009-11-05 2011-05-11 沈阳万爱普利德医药科技有限公司 一个一种前列腺素衍生物的制造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105158A1 (en) * 2000-04-25 2003-06-05 Sankyo Company, Limited Hydrates of a neuraminic acid compound and crystalline forms thereof
WO2008126943A2 (en) * 2007-04-11 2008-10-23 Daiichi Sankyo Company, Limited Method for manufacturing neuraminic acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Improved synthesis of laninamivir octanoate;FENG En-guang et al.;《Chinese Journal of Medicinal Chemistry》;20120831;第22卷(第4期);第294-301页 *

Also Published As

Publication number Publication date
EP2960237A1 (en) 2015-12-30
JPWO2013089168A1 (ja) 2015-04-27
EP2960236A1 (en) 2015-12-30
CA2859296A1 (en) 2013-06-20
US20140356625A1 (en) 2014-12-04
CN104926802A (zh) 2015-09-23
ES2640001T3 (es) 2017-10-31
JP6038808B2 (ja) 2016-12-07
CA2859296C (en) 2016-10-11
US20170114035A1 (en) 2017-04-27
BR112014014635A2 (pt) 2017-06-13
HK1199034A1 (en) 2015-06-19
KR101971311B1 (ko) 2019-04-22
CN105037309A (zh) 2015-11-11
IN2014MN00971A (enExample) 2015-05-22
CN103974945A (zh) 2014-08-06
EP2792676A4 (en) 2015-10-07
IL236766A0 (en) 2015-03-31
EP2792676A1 (en) 2014-10-22
WO2013089168A1 (ja) 2013-06-20
IL233124A0 (en) 2014-08-03
EP2960236B1 (en) 2017-06-14
KR20140102216A (ko) 2014-08-21
HK1218911A1 (en) 2017-03-17
HK1218912A1 (en) 2017-03-17
CN103974945B (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
CN113226327B (zh) 可用于治疗流感病毒感染的化合物
CN104926802B (zh) 用于制备神经氨酸衍生物的方法
CN102603691B (zh) 制备神经氨酸衍生物的方法
EP3418273B1 (fr) Dérivés de flavaglines
EP2896623A1 (en) CRYSTAL OF N-[2-({2-[(2S)-2-CYANOPYRROLIDIN-1-YL]-2- OXOETHYL}AMINO)-2-METHYLPROPYL]-2-METHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE
CN112110897B (zh) 一种氘代克里唑蒂尼及其衍生物的制备方法
ES2861062T3 (es) Procedimiento de purificación de un derivado de benzopirano, forma cristalina del mismo, y procedimiento de preparación de la forma cristalina
CN102381997A (zh) 带有氨基酸酯末端的丙泊酚羟基酸酯类化合物及其制备方法和应用
HK40050168B (en) Compounds useful to treat influenza virus infections
CN103819461A (zh) N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
CB03 Change of inventor or designer information

Inventor after: Wakayama Masakazu

Inventor after: Toriyama Fumihiko

Inventor before: Tomo Sakurai benevolence

Inventor before: Zhong Daogong

Inventor before: Wakayama Masakazu

Inventor before: Toriyama Fumihiko

Inventor before: Sang Yuantai is of a specified duration

COR Change of bibliographic data
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant